Porfimer sodium

Porfimer sodium, sold as Photofrin, is a photosensitizer used in photodynamic therapy and radiation therapy and for palliative treatment of obstructing endobronchial non-small cell lung carcinoma and obstructing esophageal cancer.

Porfimer sodium
Clinical data
AHFS/Drugs.comConsumer Drug Information
License data
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    administration
    Intravenous
    ATC code
    Legal status
    Legal status
    Pharmacokinetic data
    BioavailabilityNA
    Protein binding~90%
    Elimination half-life21.5 days (mean)
    ExcretionFecal
    Identifiers
    CAS Number
    PubChem CID
    DrugBank
    ChemSpider
    UNII
    ChEMBL
    Chemical and physical data
    FormulaC68H74N8O11 (for n=0)
    Molar mass1179.36 g/mol (for n=0) g·mol−1
    3D model (JSmol)
     NY (what is this?)  (verify)

    Porfimer is a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units.[1] In practice, a red light source emitting at 630 nm is used to excite the Porfimer oligomers.[2]

    Porfimer is Haematoporphyrin Derivative (HpD) (See PDT).

    Approvals and indications

    It was approved in Canada in 1993 for the treatment of bladder cancer.[2] It was approved in Japan in 1994 (for early stage lung cancer?).[2] It was approved by the U.S. FDA in December 1995 for esophageal cancer, and in 1998, it was approved for the treatment of early non-small cell lung cancer.[2]

    In August 2003 the FDA approved its use for Barrett's esophagus.[3]

    References

    1. "Porfimer injection Prescribing information" (PDF).
    2. "Photodynamic Therapy (PDT) for Lung Cancers". 2006. Cite journal requires |journal= (help)
    3. "FDA Patient Safety News: Show #20, October 2003". October 2003. Retrieved 2009-08-17.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.